Generic Name and Formulations:
Colchicinum 4X; per gram; 0.25mL per each pump depression; transdermal gel.
Indications for COLCIGEL:
Treatment and prophylaxis of acute gout flares.
One dose (0.25mL–1mL) = 1–4 pumps. Treatment: Apply 1–4 pumps (0.25mL–1mL) at first sign of gout flare, then 1–4 pumps (0.25mL–1mL) as needed up to every hour; max 6 pumps (1.5mL) in a 1-hour period and 16 pumps (4 doses) in a 24-hour period. May be given during prophylaxis at max 2 pumps at first sign of flare, then 2 pumps hourly up to 3 doses as needed. Wait 12 hours, then resume prophylactic dose. Prophylaxis: >16yrs: Apply 1–3 pumps (0.25mL–0.75mL) twice daily; max 6 pumps (1.5mL) in a 24-hour period. Dose modification in renal or hepatic impairment: see full labeling.
Traumatized skin. Secondary bacterial infection of affected area. Concomitant P-glycoprotein or strong CYP3A4 inhibitors (except fosamprenavir) in severe renal or hepatic impairment (life-threatening toxicity was reported with oral colchicine).
Avoid eyes. Discontinue if irritation, sensitivity, infection, or toxicity is suspected or occurs. Increased risk of neuromuscular toxicity in renal impairment or elderly patients. Renal or hepatic impairment. Undergoing dialysis (treatment): not recommended; (prophylaxis): monitor closely. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Concomitant P-glycoprotein and/or CYP3A4 inhibitors; monitor for colchicine toxicity. Concomitant statins, gemfibrozil, fibrates, and cyclosporine may potentiate myopathy.
Skin irritation at site of application; possible blood dyscrasias, overdosage (may be fatal).
Gel—30mL (2 X 15mL bottles)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline